** Cancer and rare diseases drugmaker Springworks Therapeutics' SWTX.O shares surge, up about 30% to $52.70 in morning trade
** Reuters reports that German healthcare and technology group, Merck KGaA MRCG.DE is in advanced talks to acquire SWTX, according to people familiar with the matter
** If the talks are successful, a deal could be signed in the coming weeks, according to Reuters' sources
** Both Springworks and Merck declined to comment
** SWTX stock has risen 12% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.